Apogee Therapeutics, Inc.
APGE
$82.93
-$1.67-1.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.95M | 19.61M | 17.10M | 17.46M | 16.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.77M | 78.06M | 71.28M | 73.17M | 63.10M |
| Operating Income | -82.77M | -78.06M | -71.28M | -73.17M | -63.10M |
| Income Before Tax | -74.03M | -69.33M | -64.96M | -66.02M | -55.26M |
| Income Tax Expenses | 79.00K | 62.00K | 61.00K | 72.00K | 83.00K |
| Earnings from Continuing Operations | -74.11M | -69.39M | -65.02M | -66.10M | -55.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.11M | -69.39M | -65.02M | -66.10M | -55.34M |
| EBIT | -82.77M | -78.06M | -71.28M | -73.17M | -63.10M |
| EBITDA | -82.36M | -77.65M | -70.87M | -72.77M | -62.89M |
| EPS Basic | -1.06 | -1.03 | -1.11 | -1.13 | -0.95 |
| Normalized Basic EPS | -0.66 | -0.64 | -0.69 | -0.71 | -0.59 |
| EPS Diluted | -1.06 | -1.03 | -1.11 | -1.13 | -0.95 |
| Normalized Diluted EPS | -0.66 | -0.64 | -0.69 | -0.71 | -0.59 |
| Average Basic Shares Outstanding | 69.67M | 67.36M | 58.77M | 58.43M | 58.20M |
| Average Diluted Shares Outstanding | 69.67M | 67.36M | 58.77M | 58.43M | 58.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |